Skip to content
My WebMD Sign In, Sign Up

HPV/Genital Warts Health Center

Font Size
A
A
A

HPV Vaccine: Good News, Bad News

Vaccine Stops 2 Cervical Cancer Viruses -- but Only 'Modest' Overall Cancer Protection Seen
By
WebMD Health News
Reviewed by Louise Chang, MD

Cervical Cancer Vaccine Success

May 9, 2007 -- The Gardasil vaccine is extremely effective in protecting women against precancerous lesions caused by the human papillomavirus types (HPVs) that cause 70% of cervical cancers and most cases of genital warts.

That's the good news from two huge, international clinical trials. The not-so-good news: Among sexually experienced 15- to 26-year-old women -- some of whom already have HPV infection -- the vaccine is far less effective in protecting against dangerous cervical lesions.

The FUTURE 1 trial enrolled nearly 5,500 women aged 16 to 24. The FUTURE II trial enrolled more than 12,000 women aged 15 to 26. Three-year results from both trials appear in the May 10 issue of The New England Journal of Medicine.

Gardasil protects against HPV that is spread mainly during sex. Women often get HPV infections soon after beginning sexual activity, although most HPV infections will not develop into cancer. So the best time to get the vaccine is in the pre-teen years, before age 13.

Or even sooner: The FDA has approved Gardasil for 9- to 26-year-olds, and the CDC has added it to the childhood vaccination schedule. Several states are debating making HPV vaccination mandatory for public school attendance, although all of these measures allow parents to opt out.

In the current studies, the vaccine looked very safe -- and very effective, says FUTURE II investigator Kevin Ault, MD, associate professor of gynecology and obstetrics at Atlanta's Emory University.

"The vaccine's efficacy is the biggest news," Ault tells WebMD. "In FUTURE I, it was 100% effective in preventing precancerous lesions and genital warts, and in FUTURE II it was 98% effective in protecting against high-grade, precancerous cervical lesions."

Different Experts, Different Opinions

Ault's numbers reflect the vaccine's effectiveness against the four HPV strains included in the vaccine -- including cervical-cancer-causing HPV-16 and HPV-18.

But these are only two of the 15 HPV strains known to cause cervical cancer. An editorial accompanying the studies notes that overall, the vaccine was no more than 20% effective in protecting women against high-grade precancerous lesions.

"This gives us a glimpse of what to expect from vaccinating a generation of 15- to 26-year-olds regardless of their sexual exposure," the editorial's co-author, Karen Smith-McCune, MD, tells WebMD. "In that general population, looking at all women who got the vaccine with all types of HPV exposure, efficacy in reducing precancer was modest -- 17% fewer cases of precancer in vaccinated women vs. the placebo group. And if you look at the most significant precancer, grade 3, there is no significant reduction among vaccinated women."

Smith-McCune is associate professor of obstetrics and gynecology at the University of California, San Francisco. She's also the mother of two daughters.

"I am not having my daughters vaccinated because the proven method of reducing their risk with regular Pap screening is very effective," she says. "In the absence of safety and efficacy data in the 11- to 12-year-old age group, and the unknown long-term effect of this vaccine in all age groups, it is too soon to recommend this vaccine."

Today on WebMD

HPV Vaccine Future
Article
STD Overview
Slideshow
 
STD Facts Quiz
Quiz
Syringes and graph illustration
Tool
 
Sex Drive Killers
Slideshow
Genital Herpes Risks Quiz
Quiz
 
Young couple holding hands
Quiz
Herpes Vaccine Study
Video
 
Condom Quiz
Quiz
HPV Symptoms Tests
Medical Reference
 
Get The STD Picture
Feature
mother and daughter talking
Tool
 

WebMD Special Sections